Neuromuscular, Cardiorespiratory and Perceptual Responses to Blood Flow Occlusion Superimposed on High Intensity Interval Training in Trained and Untrained Individuals
Summary
We are conducting a research study examining how using blood flow restriction (a common technique used in endurance exercise and weight lifting exercise) effects fatigue during high intensity cycling exercise. In a total of 8 visits, you will perform cycling while receiving muscle stimulations (non-invasive and painless) to measure your fatigue. In 4 of these visits, the blood flow to your legs will be partially restricted. This increases the pain felt during exercise (and has other impacts to the muscle and cardiovascular system) but this pain is short term and is immediately reduced upon the return of normal blood flow to the legs.
Eligibility
Eligible gender: Male, Female
Eligible ages: 18 to 45
Accepts healthy participants: Yes
Inclusion criteria:
you are eligible if:
- you are either male or female
- females that participate must be taking oral contraceptives
- you are highly endurance trained (VO2max > 60ml/Kg/min) and exercising more than 3 days/week (we will confirm VO2max values in the lab)
- you are not endurance trained (VO2max < 45 ml/kg/min) and exercising less than 3 days/week (we will confirm VO2max values in the lab)
Exclusion criteria:
you are excluded from this study if:
- you are obese (BMI >30 kg/m^2)
- you are a smoker
- you currently have a mood, neurological, cardiovascular, and/or metabolic disorder
- you had a lower limb injury within the past 6 months that currently affects currently affects your ability to exercise
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Zachary McClean
Principal investigator:
Saied Jalal Aboodarda
Clinical trial:
No
REB-ID:
REB21-0629